# Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

> **NCT05962021** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 126 (estimated)

## Conditions studied

- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Toripalimab plus Chemotherapy

## Key facts

- **NCT ID:** NCT05962021
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962021, "Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05962021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*